Metformin and Estradiol HRT Interaction: What Patients and Clinicians Need to Know

Is there a real interaction between metformin and estradiol?

Two label details answer this. The metformin tablet label has a drug interaction table with a row called 'Drugs Affecting Glycemic Control.' Its examples include estrogens and oral contraceptives. The label's instruction is to observe patients closely for loss of blood glucose control while such a drug is given, and closely for hypoglycemia when it is withdrawn [1].

The estradiol tablet label's drug interaction section deals only with CYP3A4: inducers such as St. John's wort, phenobarbital, carbamazepine and rifampin may lower estrogen levels, and inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise them [2]. Metformin is not mentioned there.

Neither label lists the other drug as a contraindication [2][1]. The labels give no figure for how large the glucose effect of estradiol is in people taking metformin.

Which direction does the glucose effect run?

The metformin label's wording points one way: estrogens sit with drugs that can push glucose up and lead to loss of glycemic control [1]. The estradiol tablet label lists reduced carbohydrate tolerance among the reactions reported with estrogen therapy [2].

A randomized trial of a different hormone regimen found fewer cases of treated diabetes. In the WHI Hormone Trial, 15,641 postmenopausal women with a uterus received conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily or placebo for 5.6 years; treated diabetes occurred in 3.5% versus 4.2%, respectively (hazard ratio 0.79, 95% CI 0.67 to 0.93), and insulin resistance fell at one year (between-group difference -0.22, p=0.03) [4]. The regimen tested was conjugated equine estrogens plus medroxyprogesterone acetate, not estradiol, and metformin was not part of it.

Does estradiol change how metformin is cleared?

Metformin is not metabolized. It is excreted unchanged in urine by tubular secretion, its renal clearance is about 3.5 times creatinine clearance, its plasma half-life is about 6.2 hours, and about 90% of an absorbed dose is cleared within 24 hours [1]. That half-life lengthens in renal impairment [1]. Estradiol is converted mainly in the liver, reversibly to estrone, with both converted to estriol, and the label says estrogens are metabolized partially by CYP3A4 [2]. Neither label lists the other drug among those that change its clearance.

What the metformin label asks prescribers to watch

The metformin label's boxed warning is lactic acidosis. The listed risk factors are renal impairment, certain interacting drugs such as carbonic anhydrase inhibitors, age 65 or older, contrast studies, surgery, hypoxic states such as acute heart failure, excessive alcohol, hepatic impairment and mitochondrial disease; estradiol is not among them [1].

The label's kidney rules apply whatever else a patient takes: eGFR before starting, contraindicated below 30 mL/min/1.73 m2, starting not recommended at 30 to 45, and benefit and risk reassessed if eGFR later falls below 45 [1]. For iodinated contrast, the label says to stop metformin at the time of or before the procedure in patients with eGFR 30 to 60, a history of liver disease, alcoholism or heart failure, or when intra-arterial contrast is used, and to recheck eGFR 48 hours afterward [1].

What the estradiol label says to watch for

Estradiol is an FDA-approved prescription estrogen, sold as oral tablets and as weekly or twice-weekly transdermal patches [2][3]. For a woman with a uterus, the tablet label says a progestin should also be started [2]. The label says to use the lowest effective dose, to reassess patients at about 3- to 6-month intervals, and to attempt to taper or stop at 3- to 6-month intervals [2]. The tablet label still carries an older boxed warning covering endometrial cancer and cardiovascular and other risks [2].

Contraindications on the tablet label: undiagnosed abnormal genital bleeding; breast cancer or a history of it, except selected palliative use; known or suspected estrogen-dependent neoplasia; active DVT or PE or a history of these; active or recent arterial thromboembolic disease such as stroke or heart attack; liver dysfunction or disease; known hypersensitivity; and known or suspected pregnancy. The 2 mg tablet contains tartrazine [2].

Blood clots: what the estradiol data show

Estradiol labels warn about venous thromboembolism, and a history of DVT or PE is a contraindication [2][3]. Route matters in observational data. The ESTHER study, a French multicenter case-control study of women aged 45 to 70 (271 cases of first idiopathic VTE and 610 matched controls), found an adjusted odds ratio of 4.2 (95% CI 1.5 to 11.6) for current oral estrogen use and 0.9 (0.4 to 2.1) for transdermal [5]. A meta-analysis of eight observational studies and nine randomized trials pooled odds ratios from the observational studies of 2.5 (1.9 to 3.4) for oral and 1.2 (0.9 to 1.7) for transdermal estrogen [6]. A UK nested case-control study of 80,396 women with VTE and 391,494 controls found an adjusted odds ratio of 1.58 (1.52 to 1.64) for oral hormone therapy; estradiol carried a lower risk than conjugated equine estrogen, and transdermal preparations were not associated with VTE risk [7]. These are observational comparisons, not randomized ones, and the patch labels still carry clot warnings and similar contraindications [3].